FBRX icon

Forte Biosciences

7.85 USD
+0.02
0.26%
At close May 16, 4:00 PM EDT
After hours
7.60
-0.25
3.18%
1 day
0.26%
5 days
16.82%
1 month
8.13%
3 months
-30.10%
6 months
28.48%
Year to date
-68.94%
1 year
-50.16%
5 years
-80.00%
10 years
-97.48%
 

About: Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).

Employees: 14

0
Funds holding %
of 7,457 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

12% more funds holding

Funds holding: 26 [Q4 2024] → 29 (+3) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

60% less capital invested

Capital invested by funds: $97.1M [Q4 2024] → $39.3M (-$57.8M) [Q1 2025]

214.08% less ownership

Funds ownership: 292.87% [Q4 2024] → 78.79% (-214.08%) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$61
677%
upside
Avg. target
$61
677%
upside
High target
$61
677%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Chardan Capital
Daniil Gataulin
17% 1-year accuracy
10 / 58 met price target
677%upside
$61
Buy
Maintained
1 Apr 2025

Financial journalist opinion

Neutral
Business Wire
2 days ago
Forte Biosciences, Inc. Announces Results and Provides Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2025 financial results and provided a clinical update. “We are looking forward to reading out the topline data from the FB102 celiac disease trial this quarter. FB102 continues to be well-tolerated and there have been no dropouts to date. Additionally, we have now dosed the first.
Forte Biosciences, Inc. Announces Results and Provides Update
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
Neutral
Business Wire
1 month ago
Forte Biosciences, Inc. Announces Results and Provides Clinical Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced full year 2024 results and provides a clinical update. “2024 was a very productive year with significant progress on the development of FB102, including the completion of the healthy volunteer study and the initiation of celiac patient trial,” said Forte Biosciences CEO Paul Wagner, Ph.D. “The celi.
Forte Biosciences, Inc. Announces Results and Provides Clinical Update
Neutral
Business Wire
3 months ago
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte's CEO, Paul Wagner, PhD will be presenting at the Guggenheim SMID Cap Biotech Conference at 1:30 PM ET on February 6th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 3rd at 10:30 AM ET, Dr. Wagner will be pr.
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
Positive
Zacks Investment Research
4 months ago
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
Positive
Zacks Investment Research
5 months ago
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
Neutral
Business Wire
5 months ago
Forte Biosciences to Host R&D Day December 3, 2024
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day on December 3, 2024 at 4:30 p.m. ET. The R&D Day will focus on the development of FB102 across autoimmune indications and will feature key thought leaders in celiac disease, vitiligo and alopecia areata including Prof. Jason Tye-Din MD, PhD, Head of Celiac Research a.
Forte Biosciences to Host R&D Day December 3, 2024
Neutral
Business Wire
5 months ago
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102. “We are appreciative of the support from new and existing investors including OrbiMed, Janus Henderson Investors, Tybourne Capital Management, Alger, Ikarian Capital, LLC, BVF Partners LP, and Th.
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
Positive
Zacks Investment Research
5 months ago
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
Neutral
Business Wire
6 months ago
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024 results and provided a business update. Third Quarter 2024 Business Highlights “We continue to make excellent progress with FB102 and have begun dosing patients in a celiac disease clinical trial. In addition to safety and tolerability, we will be assessing the histological impac.
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
Charts implemented using Lightweight Charts™